An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced a conference call with PAH experts to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension for the treatment of pulmonary arterial hypertension (PAH). The call will be held on Tuesday, July 25th at 10 a.m. EDT. Investors and analysts can access the live audio webcast through the company's website or via phone. The discussion will feature world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White.
Positive
None.
Negative
None.
- Call will be held on Tuesday, July 25th beginning at 10 a.m. EDT -
SAN DIEGO--(BUSINESS WIRE)--
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer’s management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension.
The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:
Date / Time: July 25, 10:00 a.m. EDT
Domestic Dial-in Number: 1-800-285-6670
International Dial-in Number: 713-481-0091
Conference Reference: Seralutinib Program Update Call
Live Webcast: https://edge.media-server.com/mmc/p/qzyj9utp
A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
FAQ
What is the purpose of the conference call announced by Gossamer Bio, Inc. (Nasdaq: GOSS)?
The conference call aims to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension for the treatment of pulmonary arterial hypertension (PAH).
When will the conference call take place?
The conference call will be held on Tuesday, July 25th at 10 a.m. EDT.
How can investors and analysts access the live audio webcast?
The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com or via phone using the provided dial-in numbers.
Who will be participating in the conference call?
The discussion will feature world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White.
gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
